Open access
Open access
Powered by Google Translator Translator

Cardio-oncology

Consensus Statement | Cardiac computed tomographic imaging in cardio-oncology.

22 Sep, 2022 | 13:07h | UTC

Cardiac Computed Tomographic Imaging in Cardio-Oncology: An Expert Consensus Statement from the Society of Cardiovascular Computed Tomography, Endorsed by the International Cardio-Oncology Society (ICOS) – Journal of Cardiovascular Computed Tomography

 

Commentary on Twitter

 


Large study unravels the risk factors for heart failure among childhood cancer survivors.

11 Sep, 2022 | 22:22h | UTC

Risk Factors for Heart Failure Among Pan-European Childhood Cancer Survivors – Journal of Clinical Oncology

 


Review | Cardiovascular complications of immune checkpoint inhibitors for cancer.

6 Sep, 2022 | 14:20h | UTC

Cardiovascular complications of immune checkpoint inhibitors for cancer – European Heart Journal

Related:

Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute—Cancer Therapy Evaluation Program – Journal of Clinical Oncology

Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment – Journal of the American Heart Association

Cardiotoxicity of immune checkpoint inhibitors – ESMO Open

Cardiotoxicity from immune checkpoint inhibitors – IJC Heart & Vasculature

Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology – Journal of the Formosan Medical Association

Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and Cardiogenic Shock – JACC: CardioOncology

 

Commentary on Twitter

 


#ESCCongress | 2022 ESC Guidelines on cardio-oncology.

29 Aug, 2022 | 12:17h | UTC

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC) – European Heart Journal – Cardiovascular Imaging

News Release: Advice to prevent heart problems caused by cancer therapy published today – European Society of Cardiology

Related guidelines:

Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations – Annals of Oncology

Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement from the American Heart Association – Circulation

Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline

Cardio-Onco-Hematology in Clinical Practice. Position Paper and Recommendations – Revista Espanola de Cardiologia

Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology—Part 1: acute coronary syndromes and acute pericardial diseases – European Heart Journal. Acute Cardiovascular Care

Brazilian Cardio-oncology Guideline – 2020 – Arquivos Brasileiros de Cardiologia

AHA Statement: Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors

 


Cohort Study | Association of gonadotropin-releasing hormone agonists for prostate cancer with cardiovascular disease risk and hypertension in men with diabetes.

11 Aug, 2022 | 11:54h | UTC

Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With Diabetes – JAMA Network Open

 

Commentary on Twitter

 


Cohort Study | Androgen-deprivation therapy and risk of death from cardio-vascular disease in prostate cancer patients.

28 Jul, 2022 | 13:13h | UTC

Androgen-deprivation therapy and risk of death from cardio-vascular disease in prostate cancer patients: a nationwide lithuanian population-based cohort study – The Aging Male

News Release: Hormone therapy for prostate cancer increases the risk of dying from cardiovascular disease – Taylor & Francis

 


Cohort Study | Long-term risk of cardiovascular disease mortality among classic Hodgkin lymphoma survivors.

27 Jul, 2022 | 11:53h | UTC

Long-term risk of cardiovascular disease mortality among classic Hodgkin lymphoma survivors – Cancer

Commentaries:

People with early-stage Hodgkin lymphoma face a higher risk of dying from cardiovascular disease than from cancer – Wiley

CVD Mortality Leading Cause of Death for Stage I, II Hodgkin Lymphoma – HealthDay

 


Retrospective Cohort Study | Major adverse cardiovascular events in patients with renal cell carcinoma treated with targeted therapies.

21 Jul, 2022 | 12:54h | UTC

Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma Treated With Targeted Therapies – JACC: CardioOncology

Editorial: Targeting Cardiovascular Adverse Events of Metastatic Renal Cell Carcinoma Therapies – JACC: CardioOncology

 


Review | Cardiometabolic comorbidities in cancer survivors.

19 Jul, 2022 | 13:17h | UTC

Cardiometabolic Comorbidities in Cancer Survivors: JACC: CardioOncology State-of-the-Art Review

 


Review | Cardiovascular disease in myeloproliferative neoplasms.

14 Jul, 2022 | 12:38h | UTC

Cardiovascular Disease in Myeloproliferative Neoplasms: JACC: CardioOncology State-of-the-Art Review – JACC: CardioOncology

 


How to treat renal cell carcinoma: the current treatment landscape and cardiovascular toxicities.

14 Jul, 2022 | 12:35h | UTC

How to Treat Renal Cell Carcinoma: The Current Treatment Landscape and Cardiovascular Toxicities – JACC: CardioOncology

Related: Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis – The Journal of Urology

 


Prevalence of cardiovascular disease in patients with potentially curable malignancies: a national registry dataset analysis.

14 Jul, 2022 | 12:33h | UTC

Prevalence of Cardiovascular Disease in Patients With Potentially Curable Malignancies: A National Registry Dataset Analysis – JACC: CardioOncology

Editorial: How Common Is Pre-Existing Cardiovascular Disease in Cancer Patients: What Do We Know? Does It Matter? – JACC: CardioOncology

 


Clinical recommendations to diagnose and monitor patients with transthyretin amyloid cardiomyopathy.

8 Jul, 2022 | 11:53h | UTC

Clinical recommendations to diagnose and monitor patients with transthyretin amyloid cardiomyopathy in Asia – Clinical Cardiology

Related:

Characteristics and natural history of early-stage cardiac transthyretin amyloidosis – European Heart Journal

Position Statement on Diagnosis and Treatment of Cardiac Amyloidosis – 2021 – Arquivos Brasileiros de Cardiologia

AHA Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis.

Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases – European Heart Journal

Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association – Circulation

Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis – Canadian Journal of Cardiology

AL Amyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and Management – JACC: CardioOncology

Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis – Circulation: Heart Failure

 


M-A | Risk factors for anthracycline-induced cardiotoxicity in breast cancer treatment.

7 Jul, 2022 | 12:17h | UTC

Risk Factors for Anthracycline-Induced Cardiotoxicity in Breast Cancer Treatment: A Meta-Analysis – Frontiers in Oncology

 


Stay Updated in Your Specialty

No spam, just news.